Journal: bioRxiv
Article Title: Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy
doi: 10.64898/2026.02.26.707014
Figure Lengend Snippet: Transduction of SupT1 (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).
Article Snippet: Suspension cell lines SupT1 (ATCC: CRL-1942) and Jurkat (RRID: CVCL_C831) were maintained in RPMI 1640 (Biozym Scientific) with 10% FCS, 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech).
Techniques: Transduction, Flow Cytometry
ATCC is a verified supplier 
ATCC manufactures this product 
